Valuation: ABVC BioPharma, Inc.

Market Cap 27.29M 23.71M 22.01M 20.3M 38.24M 2.61B 38.93M 261M 102M 1.29B 102M 100M 4.35B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 30.02M 26.07M 24.21M 22.33M 42.06M 2.87B 42.82M 287M 112M 1.42B 113M 110M 4.79B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.2%
Yield 2024 *
-
Yield 2025 -
1 day+6.93%
1 week-10.00%
Current month-31.65%
1 month-31.65%
3 months+4.85%
6 months-46.53%
Current year-49.30%
1 week 0.96
Extreme 0.96
1.15
1 month 0.96
Extreme 0.96
2.15
Current year 0.88
Extreme 0.8801
2.43
1 year 0.88
Extreme 0.8801
3.4
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 23/06/2023
Chief Executive Officer 39 01/07/2015
Chief Tech/Sci/R&D Officer 72 13/06/2023
Director TitleAgeSince
Chairman 39 01/07/2015
Director/Board Member 65 23/11/2017
Director/Board Member 55 23/11/2017
Date Insider Type Main position Quantity % Market Cap.
5/20/22 A Other

Chairman

7,908,805 26.0954%
8/2/21 A Other

Director

5,949 0.0243%
8/2/21 A Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
+6.93%-10.00%-62.50%-59.85% 25.52M
-0.81%-0.33%+27.15%+81.12% 55.6B
-3.74%-6.32%+42.70%+64.45% 55.2B
-0.11%+0.86%-15.63%-13.56% 23.51B
-1.58%-5.51%-3.51%+375.36% 22.35B
+2.70%-1.22%+16.05%-12.11% 20.6B
-1.23%-3.51%+25.70%-31.88% 17.45B
+2.91%-4.89%+27.64%+556.52% 15.16B
+1.16%+0.58%+51.87%+181.96% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average +0.12%-2.83%+26.13%+141.42% 23.76B
Weighted average by Cap. -1.11%-0.46%+31.26%+126.47%

Financials

2024 2025
Net sales 510K 443K 411K 379K 714K 48.65M 727K 4.87M 1.91M 24.16M 1.91M 1.87M 81.25M -
Net income -4.9M -4.26M -3.95M -3.65M -6.87M -468M -6.99M -46.82M -18.33M -232M -18.41M -18.01M -782M -7.91M -6.87M -6.38M -5.88M -11.08M -755M -11.28M -75.52M -29.57M -375M -29.7M -29.05M -1.26B
Net Debt 2.88M 2.5M 2.32M 2.14M 4.04M 275M 4.11M 27.52M 10.78M 137M 10.82M 10.59M 460M 2.73M 2.37M 2.2M 2.03M 3.82M 260M 3.89M 26.04M 10.2M 129M 10.24M 10.02M 435M
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
18
Date Price Change Volume
30/07/26 $1.080 +6.93% 118,686
29/07/26 $1.010 -4.72% 44,969
28/07/26 $1.060 +3.92% 59,303
27/07/26 $1.020 -11.30% 123,482
24/07/26 $1.150 -4.17% 84,434
  1. Stock Market
  2. Stocks
  3. ABVC Stock